Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA, Istomedica Ink Exclusive Agreement Covering Greece

NEW YORK (GenomeWeb) – Belgian cancer theranostics firm OncoDNA today announced an exclusive distribution deal granting Greek anatomic pathology laboratory Istomedica the exclusive rights to OncoDNA's products in Greece.

OncoDNA will be Istomedica's preferred supplier of clinical grade molecular theranostics using OncoDeep Dx, which links specific genes to targeted cancer treatments, and clinical cancer panels, in combination with Package Plus, a set of cancer tests based on immunohistochemical, fluorescent in situ hybridization, methylation, and other technologies.

As a result of the deal, clinicians in Greece will be able to access next-generation sequencing-based technology providing them with clinically relevant interpretations of tumors with the OncoShare web platform, OncoDNA said.

"With this distribution agreement, OncoDNA is continuing to fulfill its ambitions, using innovations based on molecular characterization of tumor to help medical doctors make the right treatment choice and better monitor tumor development in the patient," OncoDNA Founder and CEO Jean-Pol Detiffe said in a statement.
OncoDNA, an affiliated company of Belgium's Institute of Pathology and Genetics, provides NGS and IHC testing to help oncologists make drug treatment choices. Athens, Greece-based Istomedica provides full histological, IHC, and molecular testing.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.